Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Sep;3(3):675–691. doi: 10.1086/674440

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by the Pulmonary Vascular Research Institute. All rights reserved.

For permission to reuse, contact journalpermissions@press.uchicago.edu.

PMC Copyright notice

Asymmetric dimethylarginine (ADMA) decreases endothelial tube formation (A, B) in human pulmonary artery endothelial cells (HPAECs). HPAECs were treated with 18β-GA, ADMA, L-257, or rotigaptide or were overexpressing AdDDAHI, AdCx43, or AdGFP, as indicated. B shows representative images of tube formation in HPAECs treated, as indicated. Scale bar = 100 μm. One asterisk: ; two asterisks: , comparison with control; one Delta: ; two Deltas: ; three Deltas: , comparisons between ADMA + treatment and ADMA groups. .

Inline graphic — Asymmetric dimethylarginine (ADMA) decreases endothelial tube formation (A, B) in human pulmonary artery endothelial cells (HPAECs). HPAECs were treated with 18β-GA, ADMA, L-257, or rotigaptide or were overexpressing AdDDAHI, AdCx43, or AdGFP, as indicated. B shows representative images of tube formation in HPAECs treated, as indicated. Scale bar = 100 μm. One asterisk: ; two asterisks: , comparison with control; one Delta: ; two Deltas: ; three Deltas: , comparisons between ADMA + treatment and ADMA groups. .